Literature DB >> 25806320

Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?

Fred R Hirsch1.   

Abstract

Entities:  

Year:  2014        PMID： 25806320      PMCID： PMC4367675          DOI： 10.3978/j.issn.2218-6751.2014.11.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  5 in total

Review 1.  Epidermal growth factor receptor inhibition in lung cancer: status 2012.

Authors:  Fred R Hirsch; Pasi A Jänne; Wilfried E Eberhardt; Federico Cappuzzo; Nick Thatcher; Robert Pirker; Hak Choy; Edward S Kim; Luis Paz-Ares; David R Gandara; Yi-Long Wu; Myung-Ju Ahn; Tetsuya Mitsudomi; Frances A Shepherd; Tony S Mok
Journal:  J Thorac Oncol       Date:  2013-03       Impact factor: 15.609

Review 2.  Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas.

Authors:  Alexis B Cortot; Pasi A Jänne
Journal:  Eur Respir Rev       Date:  2014-09

3.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

4.  LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.

Authors:  Nobuyuki Katakami; Shinji Atagi; Koichi Goto; Toyoaki Hida; Takeshi Horai; Akira Inoue; Yukito Ichinose; Kunihiko Koboyashi; Koji Takeda; Katsuyuki Kiura; Kazuto Nishio; Yoko Seki; Ryuichi Ebisawa; Mehdi Shahidi; Nobuyuki Yamamoto
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

5.  A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

Authors:  K E Ware; T K Hinz; E Kleczko; K R Singleton; L A Marek; B A Helfrich; C T Cummings; D K Graham; D Astling; A-C Tan; L E Heasley
Journal:  Oncogenesis       Date:  2013-03-25       Impact factor: 7.485
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.